Key result
CYP2C19 loss-of-function alleles are linked to clopidogrel resistance across the MENA region.
Why the study?
Studies have examined CYP2C19 polymorphism and nongenetic factors on clopidogrel response in the Middle East and North Africa region, but consistency among them was unknown.
Does carrying CYP2C19 loss-of-function variants or possessing certain nongenetic factors reduce clopidogrel responsiveness in MENA populations?
Systematic Review
Does carrying CYP2C19 loss-of-function variants or possessing certain nongenetic factors reduce clopidogrel responsiveness in MENA populations?
The CYP2C19*2 loss-of-function allele is common in MENA populations and is significantly associated with clopidogrel resistance, underscoring the potential value of genotype-guided antiplatelet therapy in these populations.
Answers are grounded in this paper and cite their sources.
May support CYP2C19 genotyping to guide clopidogrel use in MENA patients; leaves open need for outcome trials.
Clopidogrel is the cornerstone antiplatelet used in the treatment and prevention of thrombotic events. Some studies examined the effect of CYP2C19 polymorphism and nongenetic factors on clopidogrel response in the Middle East and North Africa (MENA) region. However, the consistency among these studies is yet unknown. This study aims to estimate the prevalence of CYP2C19 genetic variants in MENA region and to evaluate the effect of these variants as well as the nongenetic factors on clopidogrel responsiveness. A systematic literature search was performed to identify relevant articles. Only observational studies were included. A total of 20 studies in 8 different populations were included. The CYP2C19*2 variant is the most prevalent loss-of-function (LOF) allele in the MENA region (1.7%-35%). The frequency of CYP2C19*17 ranged from 5.3% to 26.9%. Of the 9 studies, 6 found an association between carriers of at least 1 LOF allele and clopidogrel resistance. Older age, high body mass index, females, and the use of calcium channel blockers were associated with clopidogrel resistance as well. Association between the CYP2C19*2 allele and clopidogrel resistance is common among MENA populations. Future studies should focus on having larger sample sizes to detect other minor variant alleles and their effect on bleeding and cardiovascular outcomes.
No takes yet. Share an insight, caveat, or question.
Ali et al. (2019) conducted a systematic review in Acute coronary syndrome, stroke, or revascularization requiring clopidogrel therapy. CYP2C19 loss-of-function alleles and nongenetic risk factors vs. CYP2C19 wild-type carriers and absence of nongenetic risk factors was evaluated on Clopidogrel responsiveness (platelet reactivity or clinical cardiovascular outcomes). The CYP2C19*2 variant is the most prevalent loss-of-function allele in the MENA region, with 6 of 9 studies finding an association between carrying at least 1 loss-of-function allele and clopidogrel resistance.
Synapse has enriched 10 related papers. Consider them for comparative context: